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The search of methods to ease the diag-
nosis of Alzheimer’s disease (AD) as early
as possible is in the center of attention.
Such methods (biomarkers) are a range
of blood or CSF tests on one hand, and
several types of neuroimaging scans on
the other. Biomarkers are going to be
included not only in the neuroscience
research area but also in the diagnosis
process with a practical application in
the next years. The potential for these
biomarkers to serve diagnostic purposes
of AD has been highlighted in the pro-
posed diagnostic criteria for preclinical
AD from an NIH/NIA working group
(Sperling et al., 2011). In these crite-
ria, biomarkers are defined in terms of
whether they reflect Aβ deposition, tau
deposition, or signs of neuronal injury.
Markers of Aβ deposition include both
positron-emission tomography (PET) evi-
dence of Aβ deposition and cerebrospinal
fluid (CSF) measures of lower Aβ42 levels,
using a variety of specific ligands. Markers
of tau accumulation include CSF measures
of increased total tau or phosphorylated-
tau (p-tau). Together with low CSF Aβ42,
elevated CSF tau provides a high likeli-
hood of progression to AD in patients with
MCI (mild cognitive impairment). A third
group of biomarkers reflect biochemical
changes related to processes such as cell
death, synaptic damage, oxidative stress,
or inflammation that may be part of the
cascade of events that mediate damage, or
the response to damage, in AD. This is a
field, as many others in science, that suf-
fers a quick evolution every year; and the
moment of apply biomarkers in clinical
practice is coming. It is necessary to make
the clinical community aware of these sci-
entific advances in a clear and concise
manner, as well as counting with refer-
ences that can guide our clinical practice
with a consensus point of view.
Many of the images coming both from
laboratory and neuroimaging studies are
very illustrative. These images, accompa-
nied by a short description, can perfectly
explain the main results and usefulness
of each biomarker. And this is just what
the Atlas created by Dr Manuel Menéndez
does (Menéndez González, 2011). The
objective of this book is to summarize the
most important studies made in this field.
Few publications have systematically com-
piled results on this topic and none as an
atlas. The book starts clarifying concepts as
“biomarker”, “mild cognitive impairment”
and other preclinical conditions, and then
focus on classification and description
of all biomarkers for AD. A collection
of imagines selected from outstanding
research studies are provided for both
laboratory and neuroimaging biomarkers.
Finally the author finishes with a chapter
on the rational use of biomarkers for AD
in the clinical setting.
Readers will be interested in this pub-
lication because it allows reviewing the
current status of research at the time
that visualizing outstanding results eas-
ily. The possibility of coming across an
optimal and well done review of biomark-
ers for AD is crucial not only for exper-
tees, but also for the large public seeking
to make a first approach to the world
of biomarkers for AD. Such an easy to
use manual, with the purpose to make
the broad and often confusing biomark-
ers discussion surrounding AD accessible
to a wider audience, notably in the clinic,
is invaluable. The contents seem adequate,
and Dr. Menéndez has a well-established
track record in this field that ensures the
quality of the final product, and there-
fore I am certain the scientific contents are
solid. Overall it is a solid and timely pro-
posal, at a competitive price range, which
I am sure will make an impact where
it matters the most, in the clinic with
patients.
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